Targeting pain in Parkinson's disease

Affiliations

¹ Parkinson and Movement Disorders Unit, IRCCS Hospital San Camillo, Venice, Italy. Electronic address: angelo3000@yahoo.com.
² Department of Neurological and Movement Sciences, University of Verona, Verona, Italy.

Comment

Angelo Antonini et al. Lancet Neurol. 2015 Dec.

. 2015 Dec;14(12):1144-5.

doi: 10.1016/S1474-4422(15)00286-0. Epub 2015 Oct 19.

¹ Parkinson and Movement Disorders Unit, IRCCS Hospital San Camillo, Venice, Italy. Electronic address: angelo3000@yahoo.com.
² Department of Neurological and Movement Sciences, University of Verona, Verona, Italy.

No abstract available

Comment on

Prolonged-release oxycodone-naloxone for treatment of severe pain in patients with Parkinson's disease (PANDA): a double-blind, randomised, placebo-controlled trial.
Trenkwalder C, Chaudhuri KR, Martinez-Martin P, Rascol O, Ehret R, Vališ M, Sátori M, Krygowska-Wajs A, Marti MJ, Reimer K, Oksche A, Lomax M, DeCesare J, Hopp M; PANDA study group. Trenkwalder C, et al. Lancet Neurol. 2015 Dec;14(12):1161-70. doi: 10.1016/S1474-4422(15)00243-4. Epub 2015 Oct 19. Lancet Neurol. 2015. PMID: 26494524 Clinical Trial.